The CD12 trial isn't close to being fully enrolled so the only way we see results soon is:

If the independent monitoring committee decides to stop the trial because the results are so overwhelmingly good, which Nader didn't seem to put forth as strong possibility yesterday. It is a very high bar clear in general so it's smart to think of that happening as unlikely.

Or Cytodyn can decide to unblind the data themselves prematurely and take the chance on the study being strong enough after only half enrollment.